Article Details

Merck rebounds to win a milestone immunotherapy approval in early breast cancer

Retrieved on: 2021-07-27 15:44:19

Tags for this article:

Click the tags to see associated articles and topics

Merck rebounds to win a milestone immunotherapy approval in early breast cancer. View article details on hiswai:

Excerpt

Since 2017, the FDA has cleared Keytruda and Roche's Tecentriq for triple-negative tumors that have already spread. Both companies have worked to ...

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up